STAT+: FDA pauses Regenxbio gene therapy trial again for safety concerns
RegulatoryrejectedNegative
AI Analysis
Summary
The FDA has placed a hold on a Regenxbio gene therapy trial following the emergence of new safety concerns. This marks the second pause on this trial program.
Clinical Trial Data
Outcome Details
FDA placed hold on gene therapy trial due to new safety concerns
Importance:8/10
Sentiment:
-0.90
FDA holdgene therapysafety concernsclinical trial
Related Companies
Read the original article
Published by STAT News on August 24, 2026 11:59 AM